logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Why Vertex's and CRISPR Therapeutics’ Stocks Are Rallying

Vertex and CRISPR Therapeutics While some groups are doubting the gene editing capability of CRISPR gene editing Vertex’s ( VRTX ) scientists enjoyed what they experienced during their clinical collaboration with CRISPR Therapeutics ( CRSP ), until now. Vertex felt...

Read More

June 7, 2019

0

More promising news for Array from its melanoma combination clinical trial

Array BioPharma (ARRY)  announced updated results from the Phase 3 COLUMBUS trial in  BRAF -mutant advanced melanoma. The results showed that the median overall survival (mOS ) was 33.6 months  for patients treated with the combination of encorafenib and binimetinib compared...

Read More

June 5, 2018

0

Reata Pharmaceuticals: A Successful Treatment for Alport Syndrome

Reata Pharmaceuticals CARDINAL Study Met Primary and Key Secondary Endpoints Reata Pharmaceuticals ( RETA ) announced that the Phase 3 portion of the CARDINAL study of bardoxolone methyl (bardoxolone) in patients with chronic kidney disease ( CKD ) caused by...

Read More

November 13, 2019

0

CRISPR Editing and the two published studies

Slashing of the CRISPR gene editing companies’ stocks, including  CRISPR Therapeutics (CRSP), Editas (EDIT) and   Intellia (NTLA)  is caused by two studies published in Nature Medicine, which revealed that cells whose genes are edited by  CRISPR/ Cas9 could develop...

Read More

June 12, 2018

0

PTC Therapeutics' Product Risdiplam Met Trial Endpoints for the Treatment of Spinal Muscular Atrophy

PTC Therapeutics Risdiplam Results for SMA PTC Therapeutics ( PTCT ) has positive results from part 2 of the SUNFISH trial evaluating the safety and efficacy of the product risdiplam . The results demonstrate that the trial has met its...

Read More

November 14, 2019

0

Why FDA approval of Agilent Technologies’ Assay is important to cervical cancer patients

The U.S. Food and Drug Administration (FDA) has approved  Agilent Technologies’ (NYSE: A)   Dako PD-L1 IHC 22C3 pharmDx assay  for an expanded use. The expended use is expected to help physicians to identify cervical cancer patients who are most...

Read More

June 15, 2018

0

Nektar Product NKTR-358 Shows Promise in Autoimmune and Chronic Inflammatory Conditions

Nektar Announced Results for NKTR-358  During an oral session at the Annual European Congress of Rheumatology ( EULAR ) 2019, in Madrid , Nektar Therapeutics ( NKTR ) announced results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358 ...

Read More

June 13, 2019

0

News From Four Biotech Companies and Several Treatments

AstraZeneca and Merck PARP Inhibitor Lynparza The AstraZeneca ( AZN ) and Merck ( MRK )   PARP inhibitor Lynparza (olaparib) has been granted approval in Europe for first-line maintenance monotherapy for BRCA 1 & 2 mutated advanced ovarian cancer...

Read More

June 19, 2019

0

Let the Market Plummet But Not Our stocks

The Market May be Plummeting But Prohost Picks are Not Biotech stocks had a strong start, but the gains disappeared in many stocks as the market demonstrated bearishness following a long-lasting rally. Currently, during the strong economic conditions, commentators attribute...

Read More

December 3, 2019

0

Searching for a New Promising Development-Stage Biotech Firm We Found and Picked This One

Krystal Biotech Krystal Biotech ( KRYS ) is  a gene therapy firm focused on developing topical intradermal therapeutics for rare dermatological diseases. It developed its a gene therapy product KB103 for the treatment of the broad Dystrophic epidermolysis bullosa ( DEB)...

Read More

June 25, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 75
  • 76
  • 77
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy